Metformin Hydrochloride Brown & Burk

Metformin Hydrochloride, the active ingredient in Metformin Hydrochloride Brown & Burk, is a biguanide presented as an oral tablet for oral use. It is employed to improve glycemic control in adults with type 2 diabetes mellitus by decreasing hepatic glucose production and increasing peripheral insulin sensitivity, thereby helping to lower elevated blood‑sugar levels.

GNH USA supplies Metformin Hydrochloride Brown & Burk as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide across multiple regulatory jurisdictions.

Metformin Hydrochloride is indicated for conditions within the type 2 diabetes mellitus therapeutic pathway.

- Type 2 diabetes mellitus: improves glycemic control by lowering fasting plasma glucose and HbA1c levels.

Metformin Hydrochloride may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or loss of appetite. - Diarrhea: loose stools occurring especially during treatment initiation. - Metallic taste: transient alteration in taste perception. - Vitamin B12 deficiency: reduced absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated transaminases indicating liver injury. - Hypoglycemia: when combined with insulin or insulin secretagogues.

When prescribing Metformin Hydrochloride, clinicians should observe several precautionary measures to minimize risk.

- Renal function: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function: evaluate liver enzymes to rule out significant impairment. - Risk of lactic acidosis: avoid in patients with conditions predisposing to hypoxia or severe heart failure. - Concomitant medications: review for drugs that may increase metformin levels or lactic acidosis risk. - Elderly patients: start at lower doses and monitor tolerance closely. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Metformin Hydrochloride can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure and lactic acidosis. - Cimetidine: can increase metformin plasma concentrations. - Alcohol excess: heightens risk of lactic acidosis. - Carbamazepine: may reduce metformin efficacy. - Nifedipine: potential for increased metformin levels.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and potassium. - Sulfonylureas: increased risk of hypoglycemia when combined. - Warfarin: may require INR monitoring due to altered metabolism.